Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

This example study is an open-label, multi-center, adaptive Phase 1/2 trial evaluating the safety, feasibility, and preliminary antitumor activity of allogeneic dual-target CAR-NK cell products in adults with relapsed or refractory small cell lung cancer (SCLC). Three candidate dual-target constructs (DLL3/CD56, DLL3/GD2, and CD56/GD2) will be assessed during dose escalation; a pre-specified interim assessment will select the most suitable construct to proceed into an expansion cohort at the recommended Phase 2 dose (RP2D).

Trial Details

NCT ID

NCT07744256

Phase

PHASE1 / PHASE2

Sponsor

Beijing Biotech

Status

RECRUITING

Cancer Type

Lung Cancer

Interventions

EB-DART-NK01
Lymphodepleting chemotherapy

Locations (sample)

Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

Age 18 to 75 years at the time of consent.
Histologically or cytologically confirmed small cell lung cancer (SCLC) that is metastatic, extensive-stage, or unresectable, and relapsed or refra…
At least one measurable lesion per RECIST v1.1.
ECOG performance status 0 to 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →